Inquiry into alleged GlaxoSmithKline bribery in China has led to pay fudge
7th March 2014
In the circumstances, GlaxoSmithKline’s pay committee faced a tricky problem when determining boardroom pay bonuses.
GlaxoSmithKline had a terrific 2013 apart from one incident that has the potential to damage the company severely in its most important emerging market. The big issue, of course, is the allegation that the Chinese division was engaged in rampant bribery of local doctors.